Show simple item record

dc.contributor.authorMelis, Daniela
dc.contributor.authorRossi, Alessandro
dc.contributor.authorPivonello, Rosario
dc.contributor.authorSalerno, Mariacarolina
dc.contributor.authorBalivo, Francesca
dc.contributor.authorSpadarella, Simona
dc.contributor.authorMuscogiuri, Giovanna
dc.contributor.authorCasa, Roberto D
dc.contributor.authorFormisano, Pietro
dc.contributor.authorAndria, Generoso
dc.contributor.authorColao, Annamaria
dc.contributor.authorParenti, Giancarlo
dc.date.accessioned2015-09-01T16:51:02Z
dc.date.available2015-09-01T16:51:02Z
dc.date.issued2015-07-29
dc.identifier.citationOrphanet Journal of Rare Diseases. 2015 Jul 29;10(1):91
dc.identifier.urihttp://dx.doi.org/10.1186/s13023-015-0301-2
dc.identifier.urihttp://hdl.handle.net/10724/31668
dc.description.abstractAbstract Background In GSDIa, glucose 6-phosphate (G6P) accumulates in the endoplasmic reticulum (ER); in GSDIb, G6P levels are reduced in ER. G6P availability directly modulates the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1), an ER-bound enzyme playing a key role in the development of the metabolic syndrome (MS). Objective To evaluate the prevalence of MS and Insulin Resistance (IR) in GSDIa and GSDIb patients. Patients and Methods This was a prospective study. All the enrolled patients were followed at the Department of Pediatrics “Federico II” University of Naples for 10 years. Clinical and biochemical parameters of MS and the presence of IR were recorded. The results were correlated with the biochemical parameters of GSDI-related metabolic control. 10 GSDIa patient (median age 12.10 ± 1.50), 7 GSDIb patients (median age 14.90 ± 2.20 were enrolled in the study. They were compared to 20 and 14 age and sex matched controls, respectively. 10 GSDIa patients (median age 24.60 ± 1.50) and 6 GSDIb patients (median age 25.10 ± 2.00) completed the 10-year-follow-up. At the end of the study the patients’ data were compared to 10 and 6 age and sex matched controls, respectively. Results At study entry, 20 % GSDIa patients had MS and 80 % showed 2 criteria for MS. GSDIa patients showed higher HOMA-IR than controls and GSDIb patients (p < 0.001, p < 0.05), respectively. Baseline ISI was lower in GSDIa than controls (p < 0.001). QUICKI was significantly lower in GSDIa than in controls (p < 0.001). At the end of the study 70 % of GSDIa patients had MS and 30 % showed 2 criteria for MS. HOMA-IR was higher in GSDIa than controls (p < 0.01). Baseline ISI was higher in GSDIb than controls (p < 0.005) and GSD1a (p < 0.05). QUICKI was lower in GSD1a patients than in controls (p < 0.03). VAI was higher in GSDIa patients than controls (p < 0.001) and GSDIb patients (p = 0.002). Conclusions Our data showed high prevalence of IR and MS in GSDIa patients. We speculate a possible role of 11βHSD1 modulation by G6P availability. We suggest a routine metabolic assessment in GSDIa patients.
dc.titleGlycogen storage disease type Ia (GSDIa) but not Glycogen storage disease type Ib (GSDIb) is associated to an increased risk of metabolic syndrome: possible role of microsomal glucose 6-phosphate accumulation
dc.typeJournal Article
dc.date.updated2015-07-29T18:07:52Z
dc.language.rfc3066en
dc.rights.holderMelis et al.


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record